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Objective: Characterization of altered expression of selected transcripts linked to 
inflammation in the peripheral blood of sporadic amyotrophic lateral sclerosis (sALS) 
patients at early stage of disease to increase knowledge about peripheral inflammatory 
response in sALS.
Methods: RNA expression levels of 45 genes were assessed by RT-qPCR in 22 sALS 
cases in parallel with 13 age-matched controls. Clinical and serum parameters were 
assessed at the same time.
results: Upregulation of genes coding for factors involved in leukocyte extravasation 
(ITGB2, INPP5D, SELL, and ICAM1) and extracellular matrix remodeling (MMP9 and 
TIMP2), as well as downregulation of certain chemokines (CCL5 and CXC5R), anti- 
inflammatory cytokines (IL10, TGFB2, and IL10RA), pro-inflammatory cytokines (IL-6), 
and T-cell regulators (CD2 and TRBC1) was found in sALS cases independently of 
gender, clinical symptoms at onset (spinal, respiratory, or bulbar), progression, periph-
eral leukocyte number, and integrity of RNA. MMP9 levels positively correlated with 
age, whereas CCR5, CCL5, and TRBC1 negatively correlated with age in sALS but not 
in controls. Relatively higher TNFA expression levels correlate with higher creatinine 
kinase protein levels in plasma.
conclusion: Present findings show early inflammatory responses characterized by 
upregulation of factors enabling extravasation of leukocytes and extracellular matrix 
remodeling in blood in sALS cases, in addition to increased TNFA levels paralleling 
skeletal muscle damage.
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inTrODUcTiOn
Increase in the number of astrocytes and microglia, and activation of inflammatory responses are 
major pathological marks in the anterior horn of the spinal cord in amyotrophic lateral sclerosis 
(ALS). Chronic inflammation plays the principal role in motor neuron demise and parallels the 
severity of motor neuron damage. A plethora of receptors, modulatory factors, chemokines, 
TaBle 1 | Summary of cases analyzed in the present study.
case age at plasma 
sampling
gender Diagnosis initial 
symptoms
rin value
1 60 M Control – 9.1
2 68 M Control – 9.2
3 66 F Control – 9.0
4 N/A M Control – 8.9
5 74 M Control – 8.0
6 N/A F Control – 8.3
7 76 F Control – 7.8
8 67 M Control – 6.1
9 72 F Control – 6.0
10 44 F Control – 6.0
11 66 F Control – 6.1
12 62 F Control – 6.5
13 63 F Control – 6.0
14 60 M ALS Spinal 7.4
15 63 M ALS Spinal 8.7
16 66 F ALS Bulbar 8.9
17 53 F ALS Bulbar 7.3
18 73 M ALS Bulbar 8.6
19 65 M ALS Spinal 8.9
20 43 M ALS Bulbar 8.6
21 57 F ALS Bulbar 7.4
22 65 M ALS Bulbar 7.1
23 67 M ALS Bulbar 7.4
24 73 M ALS Spinal 6.1
25 73 F ALS Spinal 6.0
26 59 F ALS Spinal 8.7
27 65 M ALS Respiratory 7.1
28 42 M ALS Bulbar 9.2
29 75 M ALS Respiratory 8.1
30 75 M ALS Bulbar 7.9
31 29 M ALS Spinal 8.3
32 77 M ALS Spinal 7.4
33 55 M ALS Spinal 8.5
34 69 M ALS Spinal 8.6
35 71 F ALS Spinal 8.7
ALS, amyotrophic lateral sclerosis; M, male; F, female; RIN, RNA integrity number.
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and anti- and pro-inflammatory cytokines are involved in this 
process at advanced stages of the disease (1–7). Inflammatory 
responses in the central nervous system are accompanied by 
modifications in blood and serum which may indicate a sys-
temic inflammatory response in ALS (8–11). Peripheral nerves, 
autonomic nervous system, and muscle are involved in ALS, 
and they are putative targets of inflammatory reactions (12–18). 
Recent studies have also shown modifications in the intestinal 
microbiota in ALS (19, 20), thus categorizing ALS as a disease 
with multisystem involvement.
The majority of studies of blood and serum in ALS are at 
middle or advanced stages of the disease with or without treat-
ment (10, 17, 21–26), but information about early stages at the 
time when the patient first asks for medical counseling and 
the disease is then diagnosed is limited (27). The purpose of 
the present study was to increase knowledge about expression 
of transcripts linked to inflammation in whole blood samples 
of sporadic ALS (sALS) patients at initial clinical stages of the 
disease. The selection of genes was conducted including repre-
sentative pro- and anti-inflammatory cytokines, chemokines, 
cytokine modulators, extracellular matrix remodeling-related 
factors, molecules involved in extravasation mechanisms, 
oxidative stress markers, and T-cell regulators. The expression 
of these molecules was assessed considering the variables RNA 
integrity, gender, clinical symptoms at onset (spinal, respiratory, 
or bulbar), disease progression, peripheral leukocyte number, 
and creatinine kinase protein levels in plasma.
MaTerials anD MeThODs
sample Description
Whole peripheral blood samples for mRNA expression 
and biochemical studies were obtained within the two first 
months after the diagnosis. Samples were obtained from 22 
sALS patients (mean age at plasma sampling 62.5  years; 16 
men and 6 women) and 13 healthy age-matched controls 
(mean age at plasma sampling 65 years; 11 men and 4 women). 
sALS patients were selected on the basis of early stage at the 
diagnosis with homogenous parameters of gender, age, and 
treatment, whereas controls were recruited on the basis of 
homogenous parameters of gender and age. Patients were 
evaluated clinically according to the main signs at onset 
(spinal, bulbar, and respiratory) and categorized according 
to disease progression as fast, expected, and slow progression 
depending on the survival or the clinical evolution in those 
still alive. Fast progression was considered in patients who 
survived less than 3  years; expected progression was con-
sidered between 3 and 5  years, and slow for those still alive 
after 5 years. The ALS Functional Rating Scale Revised (ALS-
FRS-R, version May 2015) was currently used in every case. 
No ALS cases or controls suffered from infection or inflamma-
tory disorder at the time of sampling. None of them complained 
of systemic disease and none received any treatment related to 
ALS. No familial forms of ALS for C9ORF72, SOD1, TARDBP, 
and FUS mutations were detected when DNA of each patient was 
sequenced. Blood samples from sALS cases and age-matched 
controls were obtained following signed informed consent and 
approval by Clinical Research Ethics Committee (CEIC) of the 
Bellvitge University Hospital. A summary of cases is shown 
in Table 1.
Blood collection
In addition to current blood samples for hemogram and 
biochemical parameters, whole blood samples were collected 
using PAXgene Blood RNA Tube (PAXgene Blood RNA Tube, 
PreAnalytiX, Qiagen® GmbH, Hilden, GE) collecting system. 
Two PAXgene Blood RNA tubes were obtained per case. Samples 
were collected at the first visit once the clinical diagnosis was 
established. Tubes were kept for 2  h at room temperature to 
ensure lysis of blood cells and then stored at −20°C for 24  h. 
Thereafter, tubes were transferred to −80°C for at least 7  days 
prior to processing.
White Blood cells (WBc) counting
Blood was collected in EDTA 3 mL tubes and analyzed using flow-
cytometry equipment. Technicon H-1, H-2, and H-3 apparatuses 
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are discrete analyzers that perform complete blood and platelet 
counts, and leukocyte differential count. The instrument has 
a tungsten halogen light source and cytometer for leukocyte 
peroxidase analysis, with the addition of a helium-neon red laser 
for RBC/platelet and basophil determinations. Red blood cells 
are lysed, and fixed leukocytes flow in a stream sheath—a layer 
of inert liquid of the same refractive index. The stream sheath 
serves to narrow the sample stream, which prevents clogging 
and keeps the flow cell clean. Within the cell flow, cells are clas-
sified one by one on the basis of size (determined by a dark-field 
light scatter detector) and cytochemical peroxidase reaction. 
Measurement of the peroxidase activity is sufficient for most of 
the WBC differential classification. Lymphocytes are identified 
as small, unstained cells. Large atypical lymphocytes, plasma 
cells, and some blasts are characterized as “large unstained cells” 
(LUCs). Eosinophils exhibit the strongest peroxidase activity 
and appear smaller than neutrophils because they absorb some 
of their own scatter signal. Neutrophils are large and have mod-
erate peroxidase activity. Monocytes have somewhat weaker 
peroxidase staining and are, therefore, in the area to the left of 
the neutrophils and to the right of the LUCs. The instrument’s 
computer automatically performs cluster analysis of the WBC 
subpopulations. The Technicon systems provide both relative 
(per cent) and absolute (×109 cells/L) cell counts for neutrophils, 
eosinophils, basophils, monocytes, and LUCs.
Quantitative Determination of creatine 
Kinase (cK) in Blood samples
Kinetic determination of CK was based upon IFCC (Inter-
national Federation of Clinical Chemistry and Laboratory 
Medicine) and DGKC (Deutsche Gesellschaft für Klinische 
Chemie). The principle of the method is based on the ability of 
CK to catalyze the conversion of creatine phosphate and ADP 
to creatine and ATP. ATP and glucose are converted to ADP 
and glucose-6-phosphate by hexokinase. Glucose-6-phosphate 
dehydrogenase oxidizes glucose-6-phosphate to 6-phospho-
gluconate, reducing NADP to NADPH. The rate of conversion 
of NADP/NADPH, monitored at 340  nm, is proportional to 
CK activity. N-acetyl cysteine (NAC) is added as an activator 
of CK (28, 29).
rna extraction and rT-qPcr
PAXgene Blood RNA tubes were incubated overnight at 4°C 
in a shaker-plate to equilibrate the temperature and increase 
yields and then at room temperature for 2 h before starting the 
procedure. RNA from frozen whole blood samples was extracted 
following the instructions of the supplier (PAXgene Blood RNA 
kit, PreAnalytiX, Qiagen® GmbH, Hilden, GE). RNA integrity 
number (RIN) and 28S/18S ratios were determined with the 
Agilent Bioanalyzer (Agilent Technologies Inc., Santa Clara, 
CA, USA) to assess RNA quality. RNA concentration was evalu-
ated using a NanoDrop™ Spectrophotometer (Thermo Fisher 
Scientific, Carlsbad, CA, USA). RIN values are shown in Table 1. 
Complementary DNA (cDNA) was prepared using the High-
Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA, USA) following the protocol provided by the 
supplier. Parallel reactions for each RNA sample were run in 
the absence of MultiScribe Reverse Transcriptase to assess lack 
of genomic DNA contamination. TaqMan RT-qPCR assays were 
performed in duplicate for each gene on cDNA samples in 384-
well optical plates using an ABI Prism 7900 Sequence Detection 
system (Applied Biosystems, Life Technologies, Waltham, MA, 
USA). For each 10 µL TaqMan reaction, 4.5 µL cDNA was mixed 
with 0.5 µL 20× TaqMan Gene Expression Assays and 5 µL of 
2× TaqMan Universal PCR Master Mix (Applied Biosystems). 
The identification numbers and names of TaqMan probes are 
shown in Table 2. Probes were selected on the basis of our pre-
vious observations of inflammatory changes in the spinal cord 
and frontal cortex in sALS (7) together with additional markers 
linked to extravasation mechanisms and extracellular matrix 
remodeling. Mean values of two house-keeping genes, glucu-
ronidase beta (GUS-β) (30) and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (31), were used as internal controls for 
normalization. The reactions were carried out using the following 
parameters: 50°C for 2 min, 95°C for 10 min, and 40 cycles at 
95°C for 15 s, and at 60°C for 1 min. Finally, all TaqMan PCR 
data were captured using the Sequence Detection Software (SDS 
version 2.2.2, Applied Biosystems). Samples were analyzed with 
the double-delta cycle threshold (ΔΔCT) method.
statistical analysis
The normality of distribution of fold change values was ana-
lyzed with the Kolmogorov–Smirnov test. The non-parametric 
Mann–Whitney test was performed to compare each group 
when values did not follow a normal distribution, whereas 
the unpaired t-test was used for normal variables. Statistical 
analysis and graphic design were performed with GraphPad 
Prism version 5.01 (La Jolla, CA, USA). Results were analyzed 
with Student’s t-test. Outliers were detected using the GraphPad 
software QuickCalcs (p  <  0.05). The data were expressed as 
mean ± SEM and significance levels were set at *p < 0.05 and 
**p < 0.01 and ***p < 0.001, and tendencies at #<0.1. Pearson’s 
correlation coefficient was used to assess a possible linear asso-
ciation between two continuous quantitative variables.
resUlTs
general clinical and hematological 
Findings
Amyotrophic lateral sclerosis progression was heterogeneous 
in the present series. Hemogram was not altered in sALS patients 
with the exception of a few cases in whom slight increase of neu-
trophils and low levels of lymphocytes was observed. CK levels 
were out of range in some patients and moderately increased in 
a few sALS cases. Clinical, hematological, and biochemical data 
are summarized in Table 3.
gene expression levels
Anti-inflammatory Cytokines
IL10, coding for interleukin 10, and TGFB2, coding for trans-
forming growth factor beta 1, mRNA levels were significantly 
reduced in sALS, whereas IL10RA which codes for interleukin 





Cathepsin C CTSC Hs00175188_m1
Cathepsin S CTSS Hs00356423_m1
CD4 molecule/T-cell surface glycoprotein CD4 CD4 Hs01058407_m1
CD44 molecule CD44 Hs01075861_m1
CD8a molecule/T-cell surface glycoprotein  
CD8a Chain
CD8A Hs00233520_m1
Chemokine (C–C motif) ligand 5 CCL5 Hs00982282_m1
Chemokine (C–C motif) receptor 5 CCR5 Hs00152917_m1 
Chemokine (C–X–C motif) receptor 5 CXCR5 Hs00173527_m1
Colony stimulating factor 1 receptor CSF1R Hs00911250_m1
Colony stimulating factor 3 receptor (granulocyte) CSF3R Hs00167918_m1
C-type lectin domain family 7 member A CLEC7A Hs01124746_m1
C–X–C motif chemokine ligand 8 CXC8 Hs00174103_m1
Glyceraldehyde-3-phosphate dehydrogenase GAPDH Hs02786624_g1
Inositol polyphosphate-5-phosphatase D INPP5D Hs00183290_m1
Integrin subunit beta 2 ITGB2 Hs00164957_m1
Integrin subunit beta 4 ITGB4 Hs00173995_m1
Intercellular adhesion molecule 1 ICAM-1 Hs00164932_m1
Intercellular adhesion molecule 5 ICAM-5 Hs00170285_m1 
Interferon, gamma INFG Hs00989291_m1
Interleukin 1 beta IL1B Hs01555410_m1
Interleukin 10 IL10 Hs00961622_m1
Interleukin 10 receptor subunit alpha IL10RA Hs00155485_m1
Interleukin 10 receptor subunit beta IL10RB Hs00988697_m1
Interleukin 6 IL6 Hs00985639_m1
Interleukin 6 signal transducer IL6ST Hs00174360_m1
LFA-3 receptor CD2 Hs00233515_m1
Lymphocyte function-associated antigen 1 LFA-1 Hs00158218_m1
Macrophage inflammatory protein 1-alpha CCL3 Hs00234142_m1
Membrane-associated ring finger (C3HC4) 9 MARCH9 Hs04189729_m1
Monocyte chemotactic and activating factor CCL2 Hs00234140_m1
Metallopeptidase-9 MMP9 Hs00234579_m1
Osteopontin SPP1 Hs00959010_m1
Programmed cell death 1 ligand 2 PD1L2 Hs01057777_m1
Selectin L SELL Hs00174151_m1
Superoxide dismutase 1, soluble SOD1 Hs00533490_m1
Superoxide dismutase 2, mitochondrial SOD2 Hs00167309_m1
T cell receptor beta constant 1 TRBC1 Hs01588269_g1
TIMP metallopeptidase inhibitor 1 TIMP-1 Hs00171558_m1
TIMP metallopeptidase inhibitor 2 TIMP-2 Hs01091317_m1
Toll-like receptor 2 TLR2 Hs00610101_m1
Toll-like receptor 3 TLR3 Hs01551078_m1
Toll-like receptor 4 TLR4 Hs01060206_m1
Toll-like receptor 7 TLR7 Hs00152971_m1
Tumor growth factor B1 TGFB1 Hs00998133_m1
Tumor growth factor B2 TGFB2 Hs00234244_m1
Tumor necrosis factor receptor superfamily 
member 1A
TNFRSF1 Hs01042313_m1
Tumor necrosis factor-alpha TNFA Hs01113624_g1
Vascular endothelial growth factor A VEGFA Hs00900055_m1
β-Glucuronidase GUS-β Hs00939627_m1
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10 receptor subunit alpha showed a tendency to decrease. 
Expression levels of IL10RB and TGFB1 encoding interleukin 
10 receptor subunit beta and transforming growth factor beta 1, 
respectively, were not modified (Figure 1A).
Chemokines
Expression levels of CCL5 and CXC5R, which code for C-C motif 
chemokine ligand 5 and C-X-C motif chemokine receptor 5, 
respectively, were significantly decreased; CCR5 coding for C-C 
motif chemokine receptor 5 showed a tendency to decrease. 
No modifications were seen for C-C motif chemokine ligand 2 
(CCL2) and 3 (CCL3), and C-X-C motif chemokine 8 (CXC8) 
(Figure 1B).
Cytokine Modulators
Toll like receptors TLR2 and TLR4 mRNA expression showed 
a tendency to increase, whereas TLR3 mRNA expression was 
significantly decreased in sALS. TLR7 and other genes involved 
in cytokine modulation such as C-type lectin domain family 
7 member A (CLEC7A), colony stimulating factor 1 receptor 
(CSF1R), and colony stimulating factor 3 receptor (CSF3R) were 
not altered (Figure 1C).
Extracellular Matrix Remodeling
MMP9, coding for matrix metallopeptidase 9, and TIMP2, cod-
ing for its inhibitor protein, TIMP metallopeptidase inhibitor 
2, were significantly increased in sALS. The expression levels of 
CTSC, CTSS, TIMP1, and SPP1, coding for cathepsin C, cath-
epsin S, TIMP metallopeptidase inhibitor 1, and osteopontin, 
respectively, were similar in sALS and controls (Figure 1D).
Extravasation Mechanisms
ITGB2, coding for integrin subunit beta 2, and INPP5D, coding 
for inositol polyphosphate-5-phosphatase D, were upregulated 
in sALS. Tendency to increase was found for SELL and ICAM1, 
coding for selectin-L and intercellular adhesion molecule 1, res-
pectively. No changes were detected in the expression of ICAM5, 
ITGB4, LFA1, and MARCH9 encoding, respectively, intercel-
lular adhesion molecule 5, integrin subunit beta 4, lymphocyte 
function-associated antigen 1, and membrane associated ring-
CH-type finger 9 (Figure 1E).
Oxidative Stress Markers
Expression of catalase (CAT) and superoxide dismutase 1 (SOD1) 
genes was not modified. Superoxide dismutase 2 (SOD2) showed 
a tendency to increase in sALS (Figure 1F).
Pro-inflammatory Cytokines
IL6, coding for interleukin-6, was significantly downregulated 
in sALS cases. TNF-α coding gene TNFA showed a tendency 
to decrease. In contrast, TNFR1S, the gene coding for its recep-
tor, was significantly increased. No alterations were found in 
the remaining assessed genes IL1B, IL6ST, INFG, PD1L2, and 
VEGFA, coding for interleukin 1B, interleukin 6 signal trans-
ducer, interferon gamma, programmed cell death 1 ligand 2, and 
vascular endothelial growth factor A, respectively (Figure 1G).
T Cell Markers
Expression of CD2, coding for CD2 molecule; CD8A, coding for 
T-Cell Surface Glycoprotein CD8 Alpha Chain; and TRBC1, cod-
ing for T-cell receptor beta constant 1, was significantly decreased 
in sALS cases. The expression of CD44 and T-cell surface glyco-
protein CD4 gene (CD4) was not modified (Figure 1H).





creatinine kinase  
(cK) (μkat/l)
leukocyte populations (×10e9cells/l)








14 Expected 13.9a (≤4.50) 3.7 1.4 0.48 0.02b 0.02
15 Expected 5.5a (≤4.50) 3.4 2.1 0.46 0.21 0.04
16 Expected 3.5a (≤2.30) 6.9a 0.8b 0.37 0.04 0.04
17 Fast 5.0a (≤2.30) 4.2 1.0b 0.34 0.1 0.05
18 Fast 3.5 (≤4.50) N/A N/A N/A N/A N/A
19 Slow 0.8 (≤4.50) 4.3 1.2 0.44 0.16 0.04
20 Fast 4.6a (≤4.50) N/A N/A N/A N/A N/A
21 Expected 5.9a (≤4.50) 3.3 1.0b 0.30b 0.15 0.04
22 Expected 2.2 (≤4.50) 3.9 2.5 0.56 0.34 0.01
23 Expected 2.6 (≤4.50) 7.8a 1.0b 0.6 0.01b 0.03
24 Expected 2.8 (≤4.50) 6.6a 1.8 0.6 0.15 0.06
25 Fast 0.7 (≤4.50) 5.6 1.4 0.87 0.39 0.09
26 Fast N/A 3.6 1.6 0.49 0.11 0.02
27 Expected 8.3a (≤4.50) 7.0a 1.7 0.53 0.11 0.07
28 Fast 1.8 (≤4.50) 4.2 3.1 0.76 0.28 0.04
29 Fast N/A 6.0a 0.9b 0.74 0.08 0.03
30 Fast 3.0 (≤4.50) 4.3 1.4 0.77 0.04 0.04
31 Fast 2.1 (≤4.50) 4.2 2.1 0.63 0.19 0.08
32 Fast N/A N/A N/A N/A N/A N/A
33 Slow 2.0 (≤4.50) 3.8 2.5 0.44 0.55 0.06
34 Slow 3.5 (≤4.50) 3.5 1.8 0.38 0.19 0.06
35 Fast 11.6a (≤4.50) N/A N/A N/A N/A N/A
N/A, data not available; μkat/L, microkatals/liter.
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correlation between clinical Parameters 
and gene Transcription
Gender, ALS form of onset (spinal, bulbar, and respiratory), 
clinical progression, leukocyte counts and leukocyte types, and 
RIN values did not correlate with modifications in gene expres-
sion. However, MMP9 levels in sALS cases positively correlated 
with age (p  =  0.046) (Figure  2A). CCR5 (p  =  0.0307), CCL5 
(p = 0.016), and TRBC1 (p = 0.0076) negatively correlated with 
age (Figure  2A) in sALS. These changes were not observed in 
the control group. Importantly, patients with sALS showed 
significant relation between elevated levels of TNFA gene and 
creatinine kinase (CK) values, which were out of the normal 
range (p = 0.025) (Figure 2B).
DiscUssiOn
Peripheral inflammatory responses are common, but poorly 
defined, in human neurodegenerative diseases. Several studies 
focus on inflammatory responses in spinal cord and blood in 
sALS (1–11). The present study was geared to gain information 
about inflammatory gene expression profiles in the whole blood 
in a series of sALS patients at the beginning of clinical symptoms 
and non-treated with riluzole in order to avoid bias related to the 
treatment.
Present observations complement data from previous studies 
and point to the activation of mechanisms facilitating extravasa-
tion of WBC to target organs.
Neutrophil recruitment is supported by leukocyte adhe-
sion molecules, chemokines, and cytokines (32, 33). Increased 
expression of ITGB2 and a tendency of ICAM1 to increase in 
blood suggest that adhesion and trans-endothelial migration of 
leukocytes is facilitated in sALS (34–36). Selectin 1, encoded 
by SELL, participates in leukocyte binding to endothelial cells 
and facilitates migration of WBC (37, 38); SELL expression 
has a tendency to increase in sALS. Increased expression of 
MMP9 favors degradation of extracellular matrix components 
and facilitation of leukocyte migration (39). MMP9 is usually 
secreted in conjunction with TIMP-1, a specific inhibitor, which 
controls its proteolytic activity (40). A balance between MMP9 
and TIMP-1 proteins regulates excessive tissue degradation in 
chronic inflammation (41). However, mRNA expression levels 
of cathepsins, also involved in extracellular matrix degradation 
(42), are not modified in blood of ALS cases when compared with 
blood samples from controls.
Expression levels of CCL2 and CCL3 v, the products of which 
modulate monocyte attraction (43, 44) are not modified in sALS. 
Moreover, reduced expression of CCR5, CCL5, and CXCR5 sup-
ports reduced activation of B-cells (45).
The product of CD2 expressed in T-cells modulates T-cell 
proliferation (46), whereas the product of TRBC1 is implicated 
in T-cell activation (47). CCL5 and CCR5 encode T-cell chemo-
attractant and regulatory molecules (48, 49). Reduced mRNA 
expression of these markers suggests inhibition of T-cell signaling.
Finally, increased INPP5D mRNA expression favors a negative 
regulation of myeloid cell proliferation (50).
FigUre 1 | Gene expression of anti-inflammatory cytokines (a), chemokines (B), cytokine modulators (c), extracellular matrix remodeling-related factors  
(D), molecules involved in extravasation mechanisms (e), oxidative stress markers (F), pro-inflammatory cytokines (g), and T-cell markers (h), as revealed by 
RT-qPCR, in blood from control and sporadic amyotrophic lateral sclerosis (sALS) cases. All data were expressed as the mean ± SEM. Statistical comparisons  
were performed using unpaired t-test; significance level was set at *p < 0.05, **p < 0.01 and ***p < 0.001, and tendencies at #<0.1. A total of 13 healthy samples 
and 22 sALS samples were included in RT-qPCR analysis.
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Toll-like receptors are involved in the initiation of the inflam-
matory process (51). Reduced levels of TLR3 accompanied by 
tendency to increased TLR4 and TLR2 mRNA expression point 
to ambiguous activation signaling by Toll-like receptors.
TGFB2, IL10, and IL6 mRNAs are downregulated, and IL10RA 
and TNFA have tendency to decrease in blood in sALS when 
compared with controls. Expression levels of IL10RB, TGFB1, 
IL1β, IL6ST, INFG (coding for interferon γ), and VEGFA are not 
FigUre 2 | (a) Positive correlation between MMP9 and age at sampling, and negative correlation between age at sampling and CCL5, CCR5, and TRBC1 in 
sporadic amyotrophic lateral sclerosis (sALS) (right graphs), but not in control cases (left graphs). (B) Relation between TNFA mRNA expression levels in blood  
and creatine kinase (CK) protein levels in serum in sALS (nCK, normal CK levels; hCK, high/out of range CK levels) using Student’s t-test. Gene expression  
values correspond to fold change values of ΔΔCT.
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modified in sALS. Expression levels of assessed colony-stimulat-
ing receptors and CSF3R do not differ from control values. Even 
considering the increased expression of TNFR1S mRNA, the 
final scenario is downregulation of pro- and anti-inflammatory 
cytokines in sALS.
SOD1 transgenic mice lacking functional CD4+ T cells show 
increased motor neuron damage which is reversed following 
bone marrow transplants thus suggesting a neuroprotective 
role of CD4+ T cells (52). On the other hand, SOD1 transgenic 
mice with additional depletion of the Rag2 gene (mSOD1/
8
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RAG2−/− mice) show delayed motor neuron disease, thus sug-
gesting that mature lymphocytes produce deleterious effects on 
vulnerable motor neurons (53).
Previous studies have shown a higher percentage of IL-13-
positive CD4 and CD8 lymphocytes (8), increased numbers of 
peripheral CD8 cytotoxic T-cells and natural killer cells, together 
with decreased regulatory T (treg) lymphocytes (10) in ALS. Our 
observations show decreased expression of CD2, coding for CD2 
molecule, TRBC1, coding for T-cell receptor beta constant 1 and 
CD8 mRNA, and preserved CD4 mRNA expression. Therefore, 
additional studies are necessary to elucidate these discrepancies 
in larger series.
The present findings show a complex scenario at early clinical 
stages of sALS, including on the one hand upregulation of genes 
whose products are involved in leukocyte extravasation and 
extracellular matrix remodeling, and on the other, downregula-
tion of chemokines, anti- and pro-inflammatory cytokines, and 
lymphocyte modulators.
Positive correlation between MMP9 and age, and negative 
correlation between age and CCL5, CCR5, and TRBC1 has been 
observed in sALS but not in controls. No correlation has been 
found between present observations and first clinical manifesta-
tion, gender, and disease progression. Therefore, the present 
findings have little prognosis value.
There is only positive correlation between TNFA mRNA 
expression and CK levels. Although TNFA mRNA expression is 
lower in ALS when compared with controls, higher TNFA mRNA 
values correlate with higher CK protein levels. This observation 
points to the possibility of a link between TNFA and muscular 
damage in sALS. Previous studies have shown that muscular 
pathology is accompanied by increased expression of systemic 
inflammatory markers (17). Moreover, increased expression of 
inflammatory markers, including IL-1β and TNF-α, is found in the 
skeletal muscle at symptomatic and end-stages of SOD1(G93A) 
transgenic mice (18). However, these individual data are not suf-
ficient to advance any definitive conclusion.
Transcriptome studies at early clinical stages in SOD1(G93A) 
transgenic mice have shown deregulated pathways common to 
spinal cord, muscle and sciatic nerve; two pathways are associated 
with T cell activation, two with macrophage activation, and one 
pathway contains genes involved in co-stimulatory regulation of 
the adaptive and innate immune systems; but blood did not show 
representation of these altered pathways (54). However, genetic 
ablation of IP3 receptor 2, which modulates inflammation and 
which expression is augmented in the spinal cord in ALS and 
related mice models, increases cytokines and decreases survival 
of SOD1G93A mice (55). These studies point to involvement of 
peripheral blood cells in the inflammatory response in the spinal 
cord in ALS. Present observations show systemic inflammatory 
responses linked to extravasation of leukocytes and remodeling 
of extracellular matrix at early stages of sALS. However, the 
observed changes do not indicate the primary or secondary 
origin, and the precise link between intrinsic and peripheral 
inflammatory responses in the pathogenesis of sALS.
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